. Axial magnetic resonance image of the abdomen demonstrating large pancreatic ductal dilation without obvious mass.
Figure 2:
Intraoperative photograph demonstrating an enlarged main pancreatic duct (black arrows) and enlarged peripheral pancreatic ducts (white arrows). P rominent pancreatic duct dilation with a mass lesion within the head of the pancreas has been found to represent a primary adenocarcinoma of the pancreas in most patients. These patients are also found to have concomitant biliary dilation. Isolated significant (Ͼ2-cm) pancreatic ductal dilation has been demonstrated to occur more commonly in mucinproducing lesions of the pancreas and primarily in intraductal papillary mucinous tumors of the pancreas. 1 Neuroendocrine lesions of the pancreas represent 0.5% of all pancreatic tumors. 2 Approximately one third of neuroendocrine tumors are hormonally inactive and account for about 20% of all endocrine tumors of the pancreas. 3 Histochemically, they are identified as insulin (50% of cases), pancreatic polypeptide (40%), glucagon (30%), and somatostatin (13%) cells. Nonfunctioning pancreatic tumors are usually unifocal, except when associated with multiple endocrine neoplasia type 1 syndrome. 4 These lesions usually occur during the fourth or fifth decade of life, with an even sex distribution. 5 Because these tumors remain clinically silent during their growth, they may attain great size without causing apparent clinical findings and commonly present in an advanced stage. Other forms of nonfunctioning neuroendocrine tumors, when originating in critical locations, can be found with elevated liver function test results or, as in this case, as a dilated pancreatic duct.
Patients who present with significant pancreatic ductal dilation should be examined to rule out proximal mass lesions. Most of these patients will ultimately undergo pancreaticoduodenectomy, which establishes the final diagnosis. 
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